<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873351</url>
  </required_header>
  <id_info>
    <org_study_id>0000</org_study_id>
    <nct_id>NCT02873351</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration</brief_title>
  <official_title>Pilot Study of L-DOPA Safety and Tolerability in Patients With AMD, and Proof of Concept That L-DOPA Improves Surrogate Biomarkers in Patients With Moderate to Advanced AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Snyder, Robert W., M.D., Ph.D., P.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Snyder, Robert W., M.D., Ph.D., P.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      From 3 large patient databases, patients diagnosed with AMD who have never taken
      levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years. Patients
      who have been treated with L-DOPA containing medications have a mean age of diagnosis of AMD
      at 79 years.

      L-DOPA binds to GPR143 in the retinal pigment epithelium, and releases PEDF, which protects
      the retina and downregulates VEGF, which is the cause of neovascularization.

      The Investigators will evaluate the safety and tolerability of carbidopa-levodopa in patients
      with AMD, and measure the effects on surrogate functional biomarkers of AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related macular degeneration (AMD) is the most common cause of blindness, in individuals
      over the age of 50, in the developed world(1,2). AMD becomes more common as people age, and
      is more common in lightly pigmented individuals(3). AMD appears more common in patients with
      Parkinson's Disease, than in those without(4). The AREDS nutritional supplements are
      effective in slowing the progress of intermediate AMD(5). Most AMD is &quot;dry AMD&quot;, which
      progresses relatively slowly and may impair vision, but usually does not lead to legal
      blindness. There are two forms of AMD, &quot;wet AMD&quot; and geographic atrophy (GA), that can cause
      more profound vision loss. In aggregate they occur in about 25% patients with AMD(5). Wet AMD
      is due to new growth of abnormal blood vessels under the retina. The new blood vessels are
      believed to be due to an excessive release of vascular endothelial growth factor (VEGF) by
      the retinal pigment epithelium(RPE) cells(6). Wet AMD is now effectively treated with
      intraocular injections of VEGF inhibitors(2). Geographic Atrophy, the other form of advanced
      AMD, represents focal death of the RPE cells and overlying neurosensory retina. There is no
      current treatment for GA. It is suspected that GA is due in part to a localized inflammatory
      response, damage to RPE cells and loss of RPE cell function(7). It may also be speculated
      that stimulation of RPE cells to release a potent neurotrophic factor, pigment epithelium
      derived factor (PEDF) may slow progression of GA.

      In 2008, Dr. Brian McKay identified a receptor, G protein coupled receptor #143(GPR143), on
      the surface of RPE cells and discovered that L-DOPA was the natural ligand or stimulator of
      GPR143(8). Dr McKay showed that treatment of RPE cells with exogenous L-DOPA resulted in the
      release of additional PEDF. In subsequent work Dr McKay's group also showed that L-DOPA
      stimulation of PEDF in RPE cells was also associated with a decrease in VEGF(9). Thus, Dr
      McKay hypothesized that exogenous L-DOPA may prevent the onset of AMD or progression to wet
      AMD.

      In 2015, Dr McKay and his associates published a paper that showed that patients, who had
      been treated with L-DOPA, had a delay in the onset of AMD by 8 years, compared to patients
      who had not been treated with L-DOPA(10). In addition, those who had AMD and went on to
      develop wet AMD, did so 5 years later than those with no history of L-DOPA treatment(10).
      L-DOPA is an intermediate in the pigmentation pathway. Dr McKay and his associates suggested
      that the reason darkly pigmented races do not get AMD nearly as frequently as lighter
      pigmented races, is that they produce more pigment, and thus more L-DOPA to stimulate GPR143
      on RPE cells. According to this hypothesis, the stimulated RPE cells release PEDF and
      decrease VEGF, which together are responsible for the protective effect.

      Since there are no established animal models for AMD, and L-DOPA has a good safety profile in
      healthy volunteers and patients with Parkinson's disease(11), the Investigators propose a
      prospective experiment to determine the safety and tolerability of L-DOPA, in a population of
      patients with AMD. The participants will be made aware of potential side effects of L-DOPA,
      which are listed in the Informed Consent, during the consent process. Adverse events will be
      elicited by questioning the participants at each visit. The participants will also be advised
      to call the site, if they have any medical problem between visits.

      The Investigators will also use this safety study to examine whether L-DOPA has a positive
      effect on surrogate biomarkers of AMD. The surrogate markers to be evaluated are dark
      adaptation(12,13), best corrected visual acuity (BCVA), low luminance visual
      acuity(LLVA)(14), and the size and numbers of drusen(15) and reticular pseudodrusen(16). A
      previous trial, with retinol in 104 patients, significantly improved dark adaptation in 30
      days.(17) Therefore, the Investigators expect to see improvement with L-DOPA in a relatively
      short time. This study will also help the Investigators prepare for a Phase 3 study of L-DOPA
      in AMD.

      Pharmacology of L-DOPA and carbidopa

      L-DOPA is formed by 3-hydroxylation of tyrosine by tyrosine-3-monooxygenase (tyrosinase).(18)
      The primary metabolic pathway of L-DOPA is decarboxylation by amino acid decarboxylase to
      dopamine, which is responsible for most, but not all, of its pharmacologic effects and
      toxicity. When carbidopa is administered with L-DOPA, systemic levels of L-DOPA double and
      central nervous system (CNS) L-DOPA increases from about 1% of the administered dose to about
      4%. Levodopa freely passes from the systemic circulation into the retina and brain, but
      dopamine and carbidopa do not. Adverse events are markedly decreased when carbidopa is
      administered with L-DOPA, because systemic levels of the toxic metabolite of L-DOPA,
      dopamine, are markedly reduced. In most patients, 25 mg of carbidopa is sufficient to control
      side effects of 100 mg of L-DOPA, primarily nausea(18), by 90%. However, some patients
      require additional supplemental carbidopa. Carbidopa has very limited side effects when given
      alone(18). Therefore, the Investigators plan to use 35 mg of carbidopa with each 100 mg of
      levodopa, in order to control adverse events in almost all participants.

      L-DOPA is the natural ligand for GPR143 in the RPE cells(8). The Investigators' intent is to
      increase the L-DOPA available to RPE surface receptors (GPR 143) while minimizing peripheral
      toxicity. This concept is unique, because all other uses of L-DOPA rely on CNS conversion of
      L-DOPA to dopamine, in order to produce the desired effect(19).

      Treatments:

        1. Carbidopa-levodopa 35-100 mg dosed hs for 45 days, followed by carbidopa-levodopa 35-100
           mg dosed in the morning, with supper and hs for 45 days. The second dosing period is the
           equivalent of a moderate dose of carbidopa-levodopa in patients with Parkinson's disease
           (maximum daily dose 200-800 mg).

        2. Placebo dosed hs for 45 days, followed by placebo dosed in the morning, with supper and
           hs for 45 days.

      Placebo and active medication will be dosed as capsules, identical in appearance.

      Number of participants: Not yet recruiting, stratified by non-study eye being normal, dry AMD
      or wet AMD and randomized using a table of random numbers. Estimated screen failure rate is
      50%. The sample size is based on a successful study treating patients with impaired dark
      adaptation with retinol, which showed significant improvement in 30 days with 52 patients per
      study arm.

      Duration: 87-114 days (80-100 days of treatment). Visits 1 (screening) and 2(randomization)
      can be scheduled within 1 week. The first visit after Randomization, Visit 3, will occur
      40-50 days after Visit 2. Visit 4 (end of study) will occur 40-50 days after Visit 3. This
      schedule allows a 10 day window for study visits, for logistic reasons and patient
      convenience.

      Overall trial duration for enrollment and treatment, screening 5 patients per week, will be
      approximately 10 months.

      Primary Endpoint: A statistically significant improvement by carbidopa-levodopa treatment in
      any of: dark adaptation; BCVA; LLVA; drusen or reticular pseudodrusen measured by spectral
      domain(SD) optical coherence tomography(OCT)

      Measurements:

        1. Demographics at Visit 1;

        2. Medical History and Physical Examination at Visit 1;

        3. Electrocardiogram(ECG), complete blood count(CBC), Chem 20 and HbA1C at Visit 1;

        4. Vital signs at Visits 1,3,4,5 and 6;

        5. Non-directed assessment of adverse events at Visits 1,2, 3 and 4;

        6. Ophthalmic history and comprehensive eye examination, including dark adaptation and SD
           OCT at Visit 2 (Baseline);

        7. Low luminance questionnaire at visits 2, 3 and 4;

        8. Pill count at Visits 3 and 4;

        9. Re-measurement of dark adaptation, visual acuity under normal and low light conditions
           and SD OCT at Visits 3 and 4 (End of Study);

      Statistics: Analysis of Variance with Independent Variables:

        1. Active Drug vs Placebo;

        2. Logarithm of daily dose of active drug;

        3. Duration of treatment (measurements at Visits 3, 4, 5 and 6.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Decided to do studies in patients with AMD rather than study surrogate markers in patients
    without AMD.
  </why_stopped>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>90 +- 10 days</time_frame>
    <description>Treatment Emergent Adverse Events (AEs) will be assessed at each visit. These will be classified as mild, moderate or severe and by body organ system. All AEs will be specifically reassessed at each subsequent visit. Serious AEs will be reported to the institutional Review Board(IRB). All AEs will be aggregated by treatment arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Best Corrected Visual Acuity</measure>
    <time_frame>45 +/- 5 days and 90 +/- 10 days</time_frame>
    <description>After refraction to ascertain that the participant has the optimum correction for refractive error, standard visual acuity testing will be performed with an ETDRS chart. Results will be ascertained at 45 +/-5 and 90 +/- 10 days, due to different dosing during the first and second 45 day periods. Results will be aggregated by treatment arm and treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Low Light Visual Acuity</measure>
    <time_frame>45 +/- 5 days and 90 +/- 10 days</time_frame>
    <description>Using lenses for optimum correction for refractive error, Standard visual acuity testing will be performed using an ETDRS chart under standardized low light conditions. Results will be ascertained at 45 +/- 5 and 90 +/- 10 days, due to different dosing during the first and second 45 day periods. Results will be aggregated by treatment arm and treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dark Adaptation</measure>
    <time_frame>45 +/- 5 days and 90 +/- 10 days</time_frame>
    <description>Using an AdaptDX machine, using standardized intensity and duration of bright light, measurement of the time after bright light exposure required to adapt to dim light will be measured using rod intercept as the measurement. Results will be ascertained at 45 +/- 5 and 90 +/- 10 days, due to different dosing during the first and second 45 day periods. Results will be aggregated by treatment arm and treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Low Luminance Questionnaire Scores</measure>
    <time_frame>45 +/- 5 days and 90 +/- 10 days</time_frame>
    <description>This will be measured using a standard questionaire evaluating ability to function in low light conditions. Results will be tabulated by all correct answers and by number of correct answers on each subscale. Results will be ascertained at 45 +/- 5 and 90 +/- 10 days, due to different dosing during the first and second 45 day periods. Results will be aggregated by treatment arm and treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Optical Coherence Tomography</measure>
    <time_frame>45 +/- 5 days and 90 +/- 10 days</time_frame>
    <description>Evaluating retinal structure, including drusen and reticular pseudodrusen using a standard scanning laser device. Results will be ascertained at 45 +/- 5 and 90 +/- 10 days, due to different dosing during the first and second 45 day periods. Results will be aggregated by treatment arm and treatment period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>carbidopa-levodopa 25-100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for carbidopa-levodopa 25-100 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carbidopa-levodopa 25-100 mg</intervention_name>
    <description>included in arm description</description>
    <arm_group_label>carbidopa-levodopa 25-100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for carbidopa-levodopa 25-100 mg</intervention_name>
    <description>included in arm description</description>
    <arm_group_label>Placebo for carbidopa-levodopa 25-100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  - A diagnosis of intermediate or advanced dry AMD in at least one eye. The other
                  eye may be normal or have any stage of AMD.

               -  - If the participant is taking AREDS vitamin supplements, these supplements must
                  be continued for the duration of the study. If the participant is not taking
                  AREDS vitamin supplements, these supplements must not be started during the
                  study.

          2. Exclusion Criteria:

               -  - Any previous prescription for L-DOPA or dopamine agonist medications, or any
                  planned use of any of these agents, except for study medication, during the
                  study;

               -  - Concurrent use of monoamine oxidase (MAO) inhibitors;

               -  - With the exception of AMD or cataract or previous cataract operation; any eye
                  condition, disease, history of surgery, or trauma in either eye, which can impair
                  vision;

               -  - Neurologic conditions which can impair vision;

               -  - Parkinson's Disease;

               -  - Dark adaptation rod intercept &lt; 6.5 minutes;

               -  - Significant orthostatic hypotension, defined as a drop in systolic blood
                  pressure, immediately upon changing from the supine to standing position, of &gt;19
                  mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing
                  from the supine to standing position;

               -  - Significant ECG abnormalities, as judged by the Investigator;

               -  - Estimated glomerular filtration rate (eGFR) &lt;30 ml/min;

               -  - Liver enzymes &gt;3 X the upper limit of normal;

               -  - HbA1C &gt;9.0;

               -  - Any other significant lab abnormalities, as judged by the Investigator.

               -  - Women with childbearing potential;

               -  -Subjects who are not fluent in English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert W Snyder, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Robert W Snyder, MD, PhD, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy C Fagan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Robert W Snyder, MD, PhD, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert W Snyder, MD, PhD, PC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. Epub 2004 Dec 14.</citation>
    <PMID>15640920</PMID>
  </reference>
  <reference>
    <citation>Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008 Jun 12;358(24):2606-17. doi: 10.1056/NEJMra0801537. Review. Erratum in: N Engl J Med. 2008 Oct 16;359(16): 1736.</citation>
    <PMID>18550876</PMID>
  </reference>
  <reference>
    <citation>Bressler SB, Mu√±oz B, Solomon SD, West SK; Salisbury Eye Evaluation (SEE) Study Team. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol. 2008 Feb;126(2):241-5. doi: 10.1001/archophthalmol.2007.53.</citation>
    <PMID>18268216</PMID>
  </reference>
  <reference>
    <citation>Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014 Nov 11;20:2243-9. doi: 10.12659/MSM.890861.</citation>
    <PMID>25387009</PMID>
  </reference>
  <reference>
    <citation>Ferrara N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med. 2010 Oct;16(10):1107-11. doi: 10.1038/nm1010-1107.</citation>
    <PMID>20930754</PMID>
  </reference>
  <reference>
    <citation>Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016 May;73(9):1765-86. doi: 10.1007/s00018-016-2147-8. Epub 2016 Feb 6. Review.</citation>
    <PMID>26852158</PMID>
  </reference>
  <reference>
    <citation>Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS. L-DOPA is an endogenous ligand for OA1. PLoS Biol. 2008 Sep 30;6(9):e236. doi: 10.1371/journal.pbio.0060236.</citation>
    <PMID>18828673</PMID>
  </reference>
  <reference>
    <citation>Falk T, Congrove NR, Zhang S, McCourt AD, Sherman SJ, McKay BS. PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers. J Biomed Biotechnol. 2012;2012:278932. doi: 10.1155/2012/278932. Epub 2012 Apr 2.</citation>
    <PMID>22547925</PMID>
  </reference>
  <reference>
    <citation>Brilliant MH, Vaziri K, Connor TB Jr, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW Jr, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS. Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration. Am J Med. 2016 Mar;129(3):292-8. doi: 10.1016/j.amjmed.2015.10.015. Epub 2015 Oct 30.</citation>
    <PMID>26524704</PMID>
  </reference>
  <reference>
    <citation>Sinemet package insert (FDA approved).</citation>
  </reference>
  <reference>
    <citation>Chandramohan A, Stinnett SS, Petrowski JT, Schuman SG, Toth CA, Cousins SW, Lad EM. VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION. Retina. 2016 May;36(5):1021-31. doi: 10.1097/IAE.0000000000001002.</citation>
    <PMID>26925551</PMID>
  </reference>
  <reference>
    <citation>Owsley C, McGwin G Jr, Clark ME, Jackson GR, Callahan MA, Kline LB, Witherspoon CD, Curcio CA. Delayed Rod-Mediated Dark Adaptation Is a Functional Biomarker for Incident Early Age-Related Macular Degeneration. Ophthalmology. 2016 Feb;123(2):344-51. doi: 10.1016/j.ophtha.2015.09.041. Epub 2015 Oct 30.</citation>
    <PMID>26522707</PMID>
  </reference>
  <reference>
    <citation>Wu Z, Ayton LN, Luu CD, Guymer RH. Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. JAMA Ophthalmol. 2015 Apr;133(4):442-8. doi: 10.1001/jamaophthalmol.2014.5963.</citation>
    <PMID>25632841</PMID>
  </reference>
  <reference>
    <citation>Hongyang Zhang; Nizar Saleh Abdelfattah; David S Boyer; Srinivas R Sadda, Longitudinal Quantitative OCT Analysis of Drusen in the Fellow Eye of Patients with Unilateral Neovascular Age-Related Macular Degeneration, ARVO Annual Meeting Abstract, 2015.</citation>
  </reference>
  <reference>
    <citation>Finger RP, Chong E, McGuinness MB, Robman LD, Aung KZ, Giles G, Baird PN, Guymer RH. Reticular Pseudodrusen and Their Association with Age-Related Macular Degeneration: The Melbourne Collaborative Cohort Study. Ophthalmology. 2016 Mar;123(3):599-608. doi: 10.1016/j.ophtha.2015.10.029. Epub 2015 Dec 8.</citation>
    <PMID>26681391</PMID>
  </reference>
  <reference>
    <citation>Owsley C, McGwin G, Jackson GR, Heimburger DC, Piyathilake CJ, Klein R, White MF, Kallies K. Effect of short-term, high-dose retinol on dark adaptation in aging and early age-related maculopathy. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1310-8.</citation>
    <PMID>16565362</PMID>
  </reference>
  <reference>
    <citation>Westfall, T.C. and Westfall, D.P. Drugs Acting at Synaptic and Neuroeffector Junctions. Pharmacological Basis of Therapeutics, 11th Edition, 530-535, McGraw-Hill, 2006.</citation>
  </reference>
  <reference>
    <citation>Standaert, D.G. and Young, A.B. Treatment of Central Nervous System Degenerative Disorders. Pharmacological Basis of Therapeutics, 11th Edition, 530-535, McGraw-Hill, 2006.</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-DOPA</keyword>
  <keyword>GPR143</keyword>
  <keyword>PEDF</keyword>
  <keyword>VEGF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

